Glenmark gets approval from Australian regulator to commercialise Ryaltris
Drug maker Glenmark Pharmaceuticals on Friday said that it has received approval from Australian regulator Therapeutic Goods Administration (TGA) to20-12-2019
20-12-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals announces product approval for Ryaltris(r) in Australia20-12-2019
Glenmark Pharma receives GMP certificate from European regulator; share price gains 3%
The share touched its 52-week high Rs 706.90 and 52-week low Rs 267.30 on 31 December, 2018 and 14 November, 2019, respectively.16-12-2019
Glenmark Pharmaceuticals Ltd - 532296 - Certificate Of Compliance Issued By The European Regulator, SUKL, Czech Republic For Glenmark'S Baddi Manufacturing Facility
We would like to inform you that the Baddi manufacturing unit of Glenmark Pharmaceuticals was inspected by the leading European regulator, SUKL (State Institute for Drug control), Czech Republic in the week of Oct 21, 2019. The European regulator has just issued a certificate of compliance for the facility stating that it complies with the principles and guidelines of Good Manufacturing Practice laid down in the directive 2003/94/EC which stipulates the requirements to fulfil GMP recommendations of WHO. This is for your information and record please.16-12-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards for the half year ended 30th September, 2019. The said disclosure has also been published on the website of the Company. This is for your information and record.11-12-2019
Glenmark Pharmaceuticals Ltd - 532296 - Change Of Name Of Registrar And Share Transfer Agent From 'Karvy Fintech Private Limited' To 'Kfin Technologies Private Limited'
We have been informed by the Registrar and Share Transfer Agent of the Company that they have changed their name from 'Karvy Fintech Private Limited' to 'KFin Technologies Private Limited" with effect from December 5, 2019. We request you to take note of the above and update in your records the name of "KFin Technologies Private Limited" as Registrar and Share Transfer Agent of the Company.10-12-2019
A bull call spread on Glenmark Pharma may pay
The long-term outlook for the Glenmark Pharmaceuticals (Rs 337.30) stock will remain negative as long as it trades below 681. In the short-term, the02-12-2019
Glenmark Pharma gets USFDA nod for diabetes management drug
Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA26-11-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP,500 mg and 1000 mg26-11-2019
Glenmark Pharma shines as September quarter marks rebound in earnings
Analysts are upgrading their ratings as they expect sales momentum in the US and domestic markets to improve18-11-2019